CN117462551A - Application of indinavir and/or derivative thereof in preparation of antituberculosis drugs - Google Patents
Application of indinavir and/or derivative thereof in preparation of antituberculosis drugs Download PDFInfo
- Publication number
- CN117462551A CN117462551A CN202311811103.1A CN202311811103A CN117462551A CN 117462551 A CN117462551 A CN 117462551A CN 202311811103 A CN202311811103 A CN 202311811103A CN 117462551 A CN117462551 A CN 117462551A
- Authority
- CN
- China
- Prior art keywords
- indinavir
- tuberculosis
- medicament
- derivatives
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 title claims abstract description 69
- 229960001936 indinavir Drugs 0.000 title claims abstract description 66
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 title claims abstract description 6
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000003814 drug Substances 0.000 claims abstract description 67
- 208000015181 infectious disease Diseases 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 229940124976 antitubercular drug Drugs 0.000 claims abstract description 11
- 201000008827 tuberculosis Diseases 0.000 claims description 60
- 230000003405 preventing effect Effects 0.000 claims description 38
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 11
- 230000037396 body weight Effects 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 150000001340 alkali metals Chemical class 0.000 claims description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 5
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 150000007522 mineralic acids Chemical class 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 201000006674 extrapulmonary tuberculosis Diseases 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 18
- 210000002540 macrophage Anatomy 0.000 abstract description 14
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 8
- 208000031886 HIV Infections Diseases 0.000 abstract description 4
- 208000037357 HIV infectious disease Diseases 0.000 abstract description 4
- 241000700605 Viruses Species 0.000 abstract description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 4
- 230000003834 intracellular effect Effects 0.000 abstract description 4
- 230000003197 catalytic effect Effects 0.000 abstract description 3
- 108010010369 HIV Protease Proteins 0.000 abstract description 2
- 108010076039 Polyproteins Proteins 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 abstract description 2
- 239000002243 precursor Substances 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 238000010839 reverse transcription Methods 0.000 abstract description 2
- 230000029812 viral genome replication Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 241000725303 Human immunodeficiency virus Species 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 7
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 108010087230 Sincalide Proteins 0.000 description 5
- 238000010609 cell counting kit-8 assay Methods 0.000 description 5
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000814 tuberculostatic agent Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000036981 active tuberculosis Diseases 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 230000002365 anti-tubercular Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- -1 fatty acid esters Chemical class 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000033353 latent tuberculosis infection Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000002895 organic esters Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010056367 Joint tuberculosis Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027259 Meningitis tuberculous Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000187644 Mycobacterium vaccae Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 208000009360 Osteoarticular Tuberculosis Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000012721 SDS lysis buffer Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000022971 Tuberculous meningitis Diseases 0.000 description 1
- 206010045104 Tuberculous pleurisy Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 201000008267 intestinal tuberculosis Diseases 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 208000001223 meningeal tuberculosis Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 201000010098 pleural tuberculosis Diseases 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010038534 renal tuberculosis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Abstract
The application provides application of indinavir and/or derivatives thereof in preparing antituberculosis drugs, and relates to the technical field of medicines. Indinavir is an antiretroproteinase inhibitor, can be combined with HIV protease catalytic sites, and can inhibit the division of virus polyprotein precursor into mature functional proteins required for virus replication. Indinavir can be used with other anti-reverse transcription virus medicaments to treat HIV infection; the application finds that indinavir has the effect of inhibiting the intracellular activity of tubercle bacillus at the level of macrophages, namely the indinavir has the potential of being used as an antitubercular drug, and has important application value in the clinical treatment of HIV combined MTB infection.
Description
Technical Field
The application relates to the technical field of medicines, in particular to application of indinavir and/or derivatives thereof in preparation of antituberculosis drugs.
Background
AIDS (acquired immunodeficiency syndrome, AIDS) is an important public health problem threatening public health.
AIDS patients are immunodeficient and often combine multiple opportunistic infections, while mycobacterium tuberculosis (Mycobacterium tuberculosis, MTB) is the more common pathogen and progresses more frequently, with only HIV infection combining latent mycobacterium tuberculosis infection (Latent TB Infection, LTBI) progressing to active tuberculosis 30 times more than HIV negative. Thus, HIV interacts with, and affects, MTB, and diagnosis is complex and difficult. Early identification and discovery of tuberculosis (including LTBI and active tuberculosis), and formulation of effective anti-tuberculosis and antiviral therapy (anti-retroviral therapy, ART) regimens are the most effective key measures to reduce the risk of HIV/MTB double infection; in the related art, no medicine with the functions of preventing, controlling and promoting curative effect on HIV/MTB double infection exists.
Disclosure of Invention
The present application has been made in view of the above problems, and an object thereof is to provide an application of indinavir and/or its derivatives in preparing antitubercular drugs; the medicine can prevent and control HIV/MTB double infection.
The first aspect of the present application provides the use of indinavir and/or its derivatives in the preparation of antitubercular medicaments.
Indinavir is an antiretroproteinase inhibitor, can be combined with HIV protease catalytic sites, and can inhibit the division of virus polyprotein precursor into mature functional proteins required for virus replication. The molecular formula is as follows:
indinavir can be used with other anti-reverse transcription virus medicaments to treat HIV infection; the application finds that indinavir has the effect of inhibiting the intracellular activity of tubercle bacillus at the level of macrophages, namely the indinavir has the potential of being used as an antitubercular drug, and has important application value in the clinical treatment of HIV combined MTB infection.
Optionally, the derivative of indinavir includes pharmaceutically acceptable salts thereof.
Alternatively, the pharmacologically acceptable salts include salts with inorganic acids, organic acids, alkali metals, alkaline earth metals, and amino acids.
Optionally, the antitubercular drug is used for preventing or treating infection by tubercle bacillus.
Optionally, the preparation raw materials of the antituberculosis drug also comprise a medicinal carrier.
Optionally, the pharmaceutically acceptable carrier comprises at least one of diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption enhancers, surfactants, adsorption carriers, lubricants, sweeteners, and flavoring agents.
In a second aspect, the present application provides a medicament for preventing and/or treating tuberculosis, the active ingredient of the medicament comprises indinavir and/or derivatives thereof.
Optionally, the mass content of indinavir and/or derivative thereof in the medicine is 0.1% -99%.
Optionally, the tuberculosis comprises pulmonary tuberculosis or extrapulmonary tuberculosis.
Optionally, the drug is administered in at least one form selected from the group consisting of powders, tablets, granules, capsules, solutions, emulsions, and suspensions.
In a third aspect, the present application provides a tuberculosis treatment kit comprising the above-described medicament for preventing and/or treating tuberculosis.
Optionally, the content of indinavir and/or derivative thereof in the kit is formulated according to the following daily dosage standard:
indinavir and/or derivatives thereof: 0.1mg/kg body weight/day to 1000mg/kg body weight/day.
Drawings
In order to more clearly illustrate the embodiments of the present drawings or the technical solutions in the prior art, the drawings that are required to be used in the embodiments or the description of the prior art will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present drawings, and that other drawings may be obtained according to the structures shown in these drawings without inventive effort to a person skilled in the art.
FIG. 1 is a graph showing the effect of various concentrations of indinavir on the cell viability of THP-1 macrophages in example 1.
FIG. 2 is a graph showing the results of inhibition of Mycobacterium tuberculosis H37Rv by indinavir at macrophage level in example 2.
The achievement of the objects, functional features and advantages of the present drawings will be further described with reference to the accompanying drawings in conjunction with the embodiments.
Detailed Description
Hereinafter, embodiments of the application of indinavir and/or its derivatives in the preparation of antitubercular drugs of the present application are specifically disclosed with reference to the accompanying drawings as appropriate. However, unnecessary detailed description may be omitted. For example, detailed descriptions of well-known matters and repeated descriptions of the actual same structure may be omitted. This is to avoid that the following description becomes unnecessarily lengthy, facilitating the understanding of those skilled in the art. Furthermore, the drawings and the following description are provided for a full understanding of the present application by those skilled in the art, and are not intended to limit the subject matter recited in the claims.
The "range" disclosed herein is defined in terms of lower and upper limits, with a given range being defined by the selection of a lower and an upper limit, the selected lower and upper limits defining the boundaries of the particular range. Ranges that are defined in this way can be inclusive or exclusive of the endpoints, and any combination can be made, i.e., any lower limit can be combined with any upper limit to form a range. For example, if ranges of 60-120 and 80-110 are listed for a particular parameter, it is understood that ranges of 60-110 and 80-120 are also contemplated. Furthermore, if the minimum range values 1 and 2 are listed, and if the maximum range values 3,4 and 5 are listed, the following ranges are all contemplated: 1-3, 1-4, 1-5, 2-3, 2-4 and 2-5. In this application, unless otherwise indicated, the numerical range "a-b" represents a shorthand representation of any combination of real numbers between a and b, where a and b are both real numbers. For example, the numerical range "0-5" means that all real numbers between "0-5" have been listed throughout, and "0-5" is simply a shorthand representation of a combination of these values. When a certain parameter is expressed as an integer of 2 or more, it is disclosed that the parameter is, for example, an integer of 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12 or the like.
All embodiments and alternative embodiments of the present application may be combined with each other to form new solutions, unless specifically stated otherwise.
All technical features and optional technical features of the present application may be combined with each other to form new technical solutions, unless specified otherwise.
All steps of the present application may be performed sequentially or randomly, preferably sequentially, unless otherwise indicated. For example, the method comprises steps (a) and (b), meaning that the method may comprise steps (a) and (b) performed sequentially, or may comprise steps (b) and (a) performed sequentially. For example, the method may further include step (c), which means that step (c) may be added to the method in any order, for example, the method may include steps (a), (b) and (c), may include steps (a), (c) and (b), may include steps (c), (a) and (b), and the like.
Reference herein to "comprising" and "including" means open ended, as well as closed ended, unless otherwise noted. For example, the terms "comprising" and "comprises" may mean that other components not listed may be included or included, or that only listed components may be included or included.
The term "or" is inclusive in this application, unless otherwise specified. For example, the phrase "a or B" means "a, B, or both a and B. More specifically, either of the following conditions satisfies the condition "a or B": a is true (or present) and B is false (or absent); a is false (or absent) and B is true (or present); or both A and B are true (or present).
Tuberculosis is a chronic infectious disease caused by a mycobacterium tuberculosis complex (Mycobacterium tuberculosis complex, abbreviated as mycobacterium tuberculosis or tubercle bacillus) and can involve a whole body multi-organ system, and the most common diseased part is the lung, which accounts for 80% -90% of the total number of tuberculosis of each organ. Mycobacterium tuberculosis complex includes Mycobacterium tuberculosis (Mycobacterium tuberculosis, MTB), mycobacterium bovis, mycobacterium africanum and Mycobacterium vaccae, the main causing human diseases are Mycobacterium tuberculosis.
AIDS patients are immunodeficient and often combine multiple opportunistic infections, while mycobacterium tuberculosis is the more common pathogen and progresses more frequently, with only HIV infection combining with a latent mycobacterium tuberculosis infected person who progresses to active tuberculosis 30 times more than HIV negative. Thus, HIV interacts with, and affects, MTB, and diagnosis is complex and difficult. Therefore, controlling the spread of tuberculosis, preventing new infection by HIV, and standardizing the diagnosis and treatment of double-infected persons are important works and challenges in disease prevention and control. In the related art, no medicine with the functions of preventing, controlling and promoting curative effect on HIV/MTB double infection exists.
For this purpose, a first aspect of the embodiments of the present application provides the use of indinavir and/or its derivatives in the preparation of antitubercular drugs.
Indinavir is a non-nucleoside reverse transcriptase inhibitor, and has the molecular formula:
;
indinavir is directly combined with HIV-1 reverse transcriptase, and blocks RNA-dependent and DNA-dependent DNA polymerase activity by destroying enzyme catalytic sites, so that indinavir is a medicine for treating HIV. The embodiment of the application finds that indinavir has the effect of inhibiting the intracellular survival of tubercle bacillus at the level of macrophages, and has the potential of being used as an antitubercular drug, and has important application value in the clinical treatment of HIV combined MTB infection.
In some embodiments, the derivative of indinavir includes pharmaceutically acceptable salts thereof.
In some embodiments, the pharmacologically acceptable salts include salts with inorganic acids, organic acids, alkali metals, alkaline earth metals, and amino acids.
In some embodiments, the pharmacologically acceptable salts described herein include salts with inorganic acids, organic acids, alkali metals, alkaline earth metals, and amino acids.
In some embodiments, the inorganic acid comprises at least one of hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrobromic acid.
In some embodiments, the organic acid comprises at least one of maleic acid, fumaric acid, tartaric acid, lactic acid, citric acid, acetic acid, methanesulfonic acid, p-toluenesulfonic acid, adipic acid, palmitic acid, and tannic acid.
In some embodiments, the alkali metal comprises at least one of lithium, sodium, and potassium.
In some embodiments, the alkaline earth metal comprises at least one of calcium and magnesium.
In some embodiments, the amino acid comprises lysine.
In some embodiments, the antitubercular drug is used to prevent or treat infection by mycobacterium tuberculosis.
Mycobacterium tuberculosis, also known as Mycobacterium tuberculosis, is a causative agent of tuberculosis. Mycobacterium tuberculosis H37Rv is a strain isolated in 1905 and widely used in biomedical research worldwide, and has an animal model of tuberculosis with complete toxicity.
In some embodiments, the preventing or treating an infection by a tubercle bacillus specifically refers to killing the tubercle bacillus or inhibiting the growth and reproduction of the tubercle bacillus.
In some embodiments, the antitubercular drug formulation further comprises a pharmaceutically acceptable carrier.
In some embodiments, the pharmaceutically acceptable carrier comprises at least one of diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption enhancers, surfactants, adsorption carriers, lubricants, sweeteners, and flavoring agents.
In some embodiments, the excipient comprises at least one of lactose, polyethylene glycol, sodium citrate, dicalcium phosphate, and water.
In some embodiments, the filler comprises at least one of starch, lactose, sucrose, glucose, mannitol, and silicic acid.
In some embodiments, the binder comprises at least one of cellulose derivatives, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic.
In some embodiments, the cellulose derivative comprises carboxymethyl cellulose.
In some embodiments, the alginate comprises alginate.
In some embodiments, the humectant comprises glycerin.
In some embodiments, the disintegrant comprises at least one of agar-agar, calcium carbonate, sodium bicarbonate, potato starch, tapioca starch, alginic acid, silicate, and sodium carbonate.
In some embodiments, the absorption enhancer comprises a quaternary ammonium compound.
In some embodiments, the surfactant comprises cetyl alcohol.
In some embodiments, the adsorption carrier comprises at least one of kaolin clay, bentonite clay, and a soap clay.
In some embodiments, the lubricant comprises at least one of talc, calcium stearate, magnesium stearate, sodium lauryl sulfate, and polyethylene glycol.
In some embodiments, the dosage form of the medicament is a variety of dosage forms conventional in the art.
In a second aspect, the present application provides a medicament for preventing and/or treating tuberculosis, the active ingredient of the medicament comprises indinavir and/or derivatives thereof.
In some embodiments, the mass content of indinavir and/or its derivatives in the medicament for preventing and/or treating tuberculosis is 0.1% -99%.
In some embodiments, the mass content of indinavir and/or its derivatives in the medicament for preventing and/or treating tuberculosis is 0.1% -95%.
In some embodiments, the tuberculosis refers to various types of tuberculosis that mycobacterium tuberculosis can cause.
In some embodiments, the tuberculosis comprises tuberculosis or extrapulmonary tuberculosis.
In some embodiments, the extrapulmonary tuberculosis comprises at least one of a bone joint tuberculosis, tuberculous meningitis, tuberculous pleurisy, renal tuberculosis, and intestinal tuberculosis.
In some embodiments, the medicament for preventing and/or treating tuberculosis may be prepared in a variety of dosage forms for ease of administration.
In some embodiments, the pharmaceutical dosage form for preventing and/or treating tuberculosis is at least one of powder, tablet, capsule, soft capsule, granule, pill, oral liquid, dry suspension, drop pill, dry extract, injection and infusion.
In some embodiments, the mode of administration of the drug for preventing and/or treating tuberculosis may be a mode of administration conventional in the art, including, but not limited to, injection or oral administration.
In some embodiments, the administration by injection may be intravenous, intramuscular, intraperitoneal, intradermal, or subcutaneous injection.
In some embodiments, the agent for preventing and/or treating tuberculosis is administered orally, rectally, parenterally, intravaginally, intraperitoneally, topically, bucally, to humans and other mammals, or as an oral spray or nasal spray.
In some embodiments, the topical comprises administration to humans and other mammals by powder, ointment or drops.
The term "parenteral" as used herein refers to modes of administration including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intra-articular injection and infusion.
In some embodiments, the medicament for preventing and/or treating tuberculosis may be an oral formulation in particular, so as to be orally administered.
In some embodiments, the oral formulation is specifically a solid dosage form or a liquid dosage form; optionally, the solid dosage form is in particular a tablet, dragee, pill, powder, granule, capsule or coating; alternatively, the liquid dosage form may be, in particular, an emulsion, solution, suspension, syrup or elixir.
In some embodiments, the capsule, tablet or pill further comprises a buffer.
In some embodiments, the solid dosage forms of tablets, dragees, capsules, pills, and granules may be prepared with coatings and shells; optionally, the shell material includes an enteric coating material and other coating materials known in the pharmaceutical formulation arts.
In some embodiments, the solid dosage form incorporates an opacifying agent.
In some embodiments, the composition of the agent for preventing and/or treating tuberculosis may also be such that it releases the active ingredient only at a certain part of the intestinal tract or preferentially at a certain part of the intestinal tract in a delayed manner.
In some embodiments, the drug for preventing and/or treating tuberculosis is prepared in the form of an embedding composition using a polymer or wax.
In some embodiments, the drug for preventing and/or treating tuberculosis is formulated in a microcapsule form.
In some embodiments, the liquid dosage form in the oral formulation includes a diluent or solubilizer in addition to the drug for preventing and/or treating tuberculosis.
In some embodiments, the diluent comprises water or an organic solvent.
In some embodiments, the solubilizing agent comprises at least one of ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylene glycol, dimethylformamide, vegetable oils, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, and fatty acid esters of sorbitan.
In some embodiments, the vegetable oil comprises at least one of cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil.
In some embodiments, the medicament may be specifically an parenteral formulation.
In some embodiments, the parenteral formulation comprises an injection or a suppository.
In some embodiments, the injection is a solution, suspension, or injectable dry powder.
Injectable dry powders refer to the addition of injection water immediately prior to injection.
In some embodiments, the injection comprises, in addition to a medicament for preventing and/or treating tuberculosis, the following carriers or adjuvants: a physiologically acceptable sterile aqueous solution, non-aqueous solution, dispersion, suspension, emulsion, aqueous carrier, non-aqueous carrier, diluent, solvent or vehicle, such as, in particular, at least one of water, ethanol, polyol, vegetable oil and injectable organic ester.
In some embodiments, the polyol includes at least one of propylene glycol, polyethylene glycol, and glycerin.
In some embodiments, the vegetable oil comprises olive oil.
In some embodiments, the injectable organic ester comprises ethyl oleate.
In some embodiments, the injection may also be in the form of an injectable depot formulation.
In some embodiments, the injectable depot formulation can be prepared by forming a microcapsule matrix of the drug in a biodegradable polymer.
In some embodiments, the biodegradable polymer comprises polylactide-polyglycolide, polyorthoester, or polyanhydrides.
In some embodiments, the injectable depot formulation is capable of controlling the rate of release of the drug by the ratio of the drug to the polymer and the nature of the particular polymer employed.
In some embodiments, the injectable depot formulations may also be prepared by embedding the drug in liposomes or microemulsions which are compatible with body tissues.
In some embodiments, the injectable formulation is further subjected to a sterilization process.
In some embodiments, the sterilization process includes filtering or incorporating the sterilant in the form of a sterile solid composition with a bacteria filter.
In some embodiments, the sterile solid composition may be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
In some embodiments, suspending agents may also be included in the injectable and oral suspensions.
In some embodiments, the suspending agent comprises at least one of ethoxylated isostearyl alcohol, polyoxyethylene sorbitol, polyoxyethylene sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth.
Furthermore, in some cases, it is desirable to slow down the absorption of subcutaneously or intramuscularly injected drugs in order to prolong the effect of the drugs. This can be achieved by using liquid suspensions of crystalline or amorphous materials that are poorly water soluble; the absorption rate of the drug depends on the dissolution rate, which in turn depends on the crystal size and the crystal form, and the purpose of prolonging the drug action can be achieved by adding the above substances. In addition, delayed absorption of parenterally administered pharmaceutical forms may be accomplished by dissolving or suspending the drug in an oil vehicle.
In some embodiments, the suppositories may be used for rectal or vaginal administration; the suppositories can be prepared by mixing the drugs for preventing and/or treating tuberculosis of the present example with a suitable non-irritating excipient or carrier; the excipient or carrier is particularly preferably cocoa butter, polyethylene glycol or a suppository wax; the excipient or carrier is solid at room temperature, but liquid at the body temperature of a human or other mammal, and thus melts in the rectal or vaginal cavity to release the active compound.
In some embodiments, the medicament for preventing and/or treating tuberculosis may be a topical administration formulation, such as a powder, a spray, an ointment, and an inhalant.
Mixing the active ingredient (indinavir and/or derivatives thereof) in the medicine for preventing and/or treating tuberculosis with pharmaceutically acceptable carrier, required preservative, buffer and propellant under aseptic condition to obtain topical administration preparation; in addition, ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of the examples.
In some embodiments, the indinavir and/or derivative thereof can be specifically a liposomal formulation, administered in liposomal form. The specific preparation method of the liposome preparation is not particularly limited in the examples, and methods well known to those skilled in the art may be used.
Liposomes are commonly made in the art with phospholipids or other lipid substances; liposomes are formed from a single or multiple layers of hydrated liquid crystals dispersed in an aqueous medium, and any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. In some embodiments, the lipid is a natural and synthetic phospholipid and/or phosphatidylcholine (lecithin). In addition, the liposome-form preparation may contain a stabilizer, a preservative, an excipient, etc., in addition to the active ingredient in the drug for preventing and/or treating tuberculosis of the present application.
The preparation method of the dosage form according to the scheme is not particularly required, and the method known by the person skilled in the art is used for preparing the active ingredient in the drug for preventing and/or treating tuberculosis provided by the application into the drug with the corresponding dosage form.
The medicament for preventing and/or treating tuberculosis of the present application can be used for preventing or treating tuberculosis of mammals (such as human beings), and a subject in need thereof is provided with a prophylactically or therapeutically effective amount of the medicament for preventing and/or treating tuberculosis. The medicament for preventing and/or treating tuberculosis provided by the application can be applied in a pure form, or applied in a prodrug form, or applied in a medicament form containing the medicament for preventing and/or treating tuberculosis provided by the application.
In particular embodiments of the present application, the actual dosage level of the active ingredient (indinavir and/or derivatives thereof) in the medicaments of the present application can be varied to provide an amount of active compound effective to achieve the desired therapeutic response for a particular patient, composition and mode of administration. The dosage level will be selected based on the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and past history of the patient being treated.
In the present application, a "therapeutically and/or prophylactically effective amount" of a medicament herein for preventing and/or treating tuberculosis refers to a sufficient amount of the medicament to prevent and/or treat tuberculosis at a reasonable effect/risk ratio for any medical treatment and/or prophylaxis to treat a disorder.
The total daily amount of the medicament for preventing and/or treating tuberculosis of the present application must be decided by a physician in charge of the medical judgment within the scope of the reliable medical judgment. For any particular patient, the particular therapeutically effective dose level will depend on a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific drug used for preventing and/or treating tuberculosis; the specific composition employed; age, weight, general health, sex and diet of the patient; the administration time, administration route and excretion rate of the specific drug for preventing and/or treating tuberculosis are adopted; duration of treatment; a drug for preventing and/or treating tuberculosis used in combination with or simultaneously with the specific drug for preventing and/or treating tuberculosis; and similar factors well known in the medical arts. It is common practice in the art to start doses of the drug for the prevention and/or treatment of tuberculosis from below the level required to obtain the desired therapeutic effect and to gradually increase the dose until the desired effect is obtained.
In a third aspect, the present application provides a tuberculosis treatment kit comprising the above-described medicament for preventing and/or treating tuberculosis.
In some embodiments, the content of indinavir and/or derivative thereof in the kit is formulated according to the following daily dosage criteria:
indinavir and/or derivatives thereof: 0.1mg/kg body weight/day to 1000mg/kg body weight/day.
In some embodiments, the content of indinavir and/or derivative thereof in the kit is formulated according to the following daily dosage criteria:
indinavir and/or derivatives thereof: 0.1mg/kg body weight/day to 100mg/kg body weight/day.
In some embodiments, the content of indinavir and/or derivative thereof in the kit is formulated according to the following daily dosage criteria:
indinavir and/or derivatives thereof: 0.1mg/kg body weight/day to 10mg/kg body weight/day.
The dosage of indinavir and/or its derivatives described in this example is calculated as the amount of compound present in the unit dosage form.
In some embodiments, the indinavir and/or derivative thereof is present in the unit dosage form in an amount of from 1mg to 5000mg.
In some embodiments, the indinavir and/or derivative thereof is present in the unit dosage form in an amount of from 10mg to 500mg.
In some embodiments, the indinavir and/or derivative thereof is present in the unit dosage form in an amount of from 20mg to 300mg.
The method for differentiating THP-1 macrophages in the examples is as follows:
THP-1 (Tohoku Hospital Pediatrics-1) cells (human monocytic leukemia cells) were purchased from the national academy of sciences cell bank and cultured in 1640 medium containing 10% fetal bovine serum, 0.05mM beta-mercaptoethanol, 10mM HEPES and 1mM sodium pyruvate at 37℃with 5% CO 2 Is cultured in a cell culture chamber of (2) in a 96-well plate at a ratio of 2.5X10 per well 4 The number of cells was plated, stimulated overnight with PMA (phorbol ester) at a final concentration of 50ng/ml, allowed to differentiate into macrophages, and 24h later replaced with the 1640 medium described above.
Example 1
This example shows the effect of various concentrations of indinavir on THP-1 macrophage survival.
Determination of cell viability: after the induced differentiated macrophages are continuously cultured for 24 hours, indinavir is added, the concentration of the indinavir is 5 mu M, 10 mu M and 20 mu M respectively, three repetitions are respectively carried out on each concentration, solvent DMSO is used as a control hole, a cell-free culture medium is used as a blank hole, the temperature is 37 ℃, and the concentration of CO is 5 percent 2 And (3) continuing culturing for 48 hours, detecting the activity of the cells by using a CCK-8 kit, adding 10 mu l of CCK-8 into each hole, culturing for 2 hours in an incubator, measuring the absorbance at OD 450nm by using an enzyme-labeled instrument, and calculating the survival rate of the cells.
Cell viability was calculated as follows:
cell viability = [ (As-Ab)/(Ac-Ab) ]x100%;
as: experimental wells (cell-containing medium, CCK-8, indinavir at different concentrations);
ac: control wells (cell-containing medium, CCK-8, DMSO);
ab: blank wells (cell-free medium, CCK-8).
Fig. 1 is a dose response curve of indinavir, and the results show that there is no significant difference in the survival rate of THP-1 macrophages after treatment with different indinavir in the experimental group compared with the control group, and it is seen that indinavir has lower toxicity to THP-1.
Example 2
This example is the use of indinavir in inhibiting the growth of mycobacterium tuberculosis.
The application of the embodiment comprises the following steps:
s1, infection of mycobacterium tuberculosis: THP-1 cells were 2.5X10 per well in 24 well plates 5 The number of individual cells was induced to macrophages as described above, 25. Mu.M indinavir was added to the experimental group, the same volume of solvent DMSO was added to the control group, after pretreatment for 1H, cells were infected with Mycobacterium tuberculosis H37Rv at MOI (multiplicity of infection ) =10, washed 3 times with PBS (phosphate buffer saline, phosphate buffered saline) after 4H, and incubated at 37℃with 5% CO in 1640 complete medium 2 The culture was continued in the incubator of (2) during which the addition of 25. Mu.M indinavir in the experimental group and the control group of equal volumes of solvent DMSO was maintained.
S2, plating count CFU (Colony-Forming Units): after 4h and 72h of infection, the cells were lysed with 0.025% SDS lysate (SDS Lysis Buffer) at 10 respectively 2 、10 3 Dilution plating, bacterial incubator culture at 37 ℃ for about three weeks to count CFU.
In this example, the inhibition of 50 μm indinavir on the level of THP-1 macrophages against mycobacterium tuberculosis H37Rv is shown in fig. 2, and ns in fig. 2 represents no significant difference, and represents significantly less than 0.0001, and the result shows that indinavir can inhibit the growth of mycobacterium tuberculosis in macrophages, and compared with DMSO control group, the survival ability of mycobacterium tuberculosis is obviously reduced after indinavir is added, and the survival rate is reduced by 45-59%.
Example 3
This example is a Minimum Inhibitory Concentration (MIC) test of indinavir.
The detection steps in this embodiment are as follows:
taking a 96-well plate, adding 100 mu L of ddH into each well at the outermost periphery of the 96-well plate 2 98. Mu.L of 7H9-OADC complete medium was added to each well of O, B2-G2, and 50. Mu.L of 7H9-OADC complete medium was added to the remaining wells. 2. Mu.L of indinavir was added per well of B2-D2 and 2. Mu.L of INH (isoniazid) was added per well of E2-G2 as positive control. Double dilution from B2-G2 to B10-G10, B11-G11 was negative control wells without drug treatment, and finally 2X 10-containing wells (except ddH2O wells) were added to each well 5 CFU/50 mu L of Mycobacterium tuberculosis H37Rv bacterial liquid is placed in a bacteria incubator at 37 ℃ for 10-14 days after being sealed by a sealing film. After removal, bacterial inhibition was observed with different concentrations of drug and MIC values were read.
Table 1 shows that indinavir and INH have MIC for Mycobacterium tuberculosis H37Rv, and the result shows that the minimum inhibitory concentration of indinavir for Mycobacterium tuberculosis in vitro is more than 500 mu M and far more than the cell level use concentration, and the antituberculosis effect of indinavir at macrophage level is not directly acted on bacteria as antibiotics, but is used for inhibiting the intracellular survival of tuberculosis by regulating the host immune response through a target host. The minimum inhibitory concentration of INH on Mycobacterium tuberculosis is 0.02 mug/mL, which is consistent with the concentration range of the related technology, and the reliability of the experimental data is demonstrated as a positive control.
Table 1 shows the MIC of indinavir and INH for Mycobacterium tuberculosis H37Rv
The present application is not limited to the above embodiment. The above embodiments are merely examples, and embodiments having substantially the same configuration and the same effects as those of the technical idea within the scope of the present application are included in the technical scope of the present application. Further, various modifications that can be made to the embodiments and other modes of combining some of the constituent elements in the embodiments, which are conceivable to those skilled in the art, are also included in the scope of the present application within the scope not departing from the gist of the present application.
Claims (10)
1. Use of indinavir and/or its derivatives in the preparation of antituberculosis drugs.
2. The use according to claim 1, wherein the derivative of indinavir comprises a pharmacologically acceptable salt thereof;
and/or the pharmacologically acceptable salts include salts with inorganic acids, organic acids, alkali metals, alkaline earth metals, and amino acids.
3. The use according to claim 1, wherein the antitubercular drug is for the prevention or treatment of infection by mycobacterium tuberculosis.
4. The use of claim 1, wherein the antitubercular drug is prepared from a material further comprising a pharmaceutically acceptable carrier;
and/or the pharmaceutically acceptable carrier comprises at least one of diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption enhancers, surfactants, adsorption carriers, lubricants, sweeteners, and flavoring agents.
5. A medicament for preventing and/or treating tuberculosis, characterized in that the active ingredient of the medicament comprises indinavir and/or derivatives thereof.
6. A medicament for the prevention and/or treatment of tuberculosis according to claim 5, wherein the mass content of indinavir and/or its derivatives in the medicament is between 0.1% and 99%.
7. A medicament for the prophylaxis and/or treatment of tuberculosis according to claim 5, wherein the tuberculosis comprises tuberculosis or extrapulmonary tuberculosis.
8. A medicament for the prophylaxis and/or treatment of tuberculosis according to claim 5, wherein the medicament is administered in at least one selected from the group consisting of powder, tablet, granule, capsule, solution, emulsion and suspension.
9. A kit for the treatment of tuberculosis, characterized in that it comprises a medicament as described in any one of claims 5 to 7.
10. The tuberculosis treatment kit of claim 9, wherein the content of indinavir and/or derivatives thereof in the kit is formulated according to the following daily dosage criteria:
indinavir and/or derivatives thereof: 0.1mg/kg body weight/day to 1000mg/kg body weight/day.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311811103.1A CN117462551A (en) | 2023-12-27 | 2023-12-27 | Application of indinavir and/or derivative thereof in preparation of antituberculosis drugs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311811103.1A CN117462551A (en) | 2023-12-27 | 2023-12-27 | Application of indinavir and/or derivative thereof in preparation of antituberculosis drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117462551A true CN117462551A (en) | 2024-01-30 |
Family
ID=89633269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311811103.1A Pending CN117462551A (en) | 2023-12-27 | 2023-12-27 | Application of indinavir and/or derivative thereof in preparation of antituberculosis drugs |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117462551A (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020068761A1 (en) * | 1999-10-04 | 2002-06-06 | Bernstein Lawrence R. | Gallium complexes of 3-hydroxy-4-pyrones to treat mycobacterial infections |
AU2008214279A1 (en) * | 2007-02-08 | 2008-08-14 | Synta Pharmaceuticals Corp. | Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer |
CN101327217A (en) * | 2007-06-20 | 2008-12-24 | 中国科学院广州生物医药与健康研究院 | Use of indinavir sulfate and chloroquine in preparing compound antimalarial medicament |
CA2812372A1 (en) * | 2010-09-22 | 2012-03-29 | Craun Research Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
US20120244212A1 (en) * | 2004-11-07 | 2012-09-27 | Frederick Timothy Guilford | Enhanced method and composition for the treatment of hiv+ tuberculosis patients with anti-retroviral drugs and liposomal encapsulation for delivery of reduced glutathione |
WO2013116605A1 (en) * | 2012-02-02 | 2013-08-08 | University Of Tennessee Research Foundation | Compositions for the treatment of tuberculosis and methods of using same |
WO2013148174A1 (en) * | 2012-03-31 | 2013-10-03 | University Of Georgia Research Foundation, Inc. | New anti-mycobacterial drugs against tuberculosis |
CN110869016A (en) * | 2017-05-08 | 2020-03-06 | 葛兰素史密斯克莱知识产权发展有限公司 | Mountain fetipenem or its salts or esters for the treatment of mycobacterial infections |
-
2023
- 2023-12-27 CN CN202311811103.1A patent/CN117462551A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020068761A1 (en) * | 1999-10-04 | 2002-06-06 | Bernstein Lawrence R. | Gallium complexes of 3-hydroxy-4-pyrones to treat mycobacterial infections |
US20120244212A1 (en) * | 2004-11-07 | 2012-09-27 | Frederick Timothy Guilford | Enhanced method and composition for the treatment of hiv+ tuberculosis patients with anti-retroviral drugs and liposomal encapsulation for delivery of reduced glutathione |
AU2008214279A1 (en) * | 2007-02-08 | 2008-08-14 | Synta Pharmaceuticals Corp. | Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer |
CN101327217A (en) * | 2007-06-20 | 2008-12-24 | 中国科学院广州生物医药与健康研究院 | Use of indinavir sulfate and chloroquine in preparing compound antimalarial medicament |
CA2812372A1 (en) * | 2010-09-22 | 2012-03-29 | Craun Research Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
WO2013116605A1 (en) * | 2012-02-02 | 2013-08-08 | University Of Tennessee Research Foundation | Compositions for the treatment of tuberculosis and methods of using same |
WO2013148174A1 (en) * | 2012-03-31 | 2013-10-03 | University Of Georgia Research Foundation, Inc. | New anti-mycobacterial drugs against tuberculosis |
CN110869016A (en) * | 2017-05-08 | 2020-03-06 | 葛兰素史密斯克莱知识产权发展有限公司 | Mountain fetipenem or its salts or esters for the treatment of mycobacterial infections |
Non-Patent Citations (4)
Title |
---|
NARITA M, STAMBAUGH J J, HOLLENDER E S, ET AL.: "Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis", 《 CLINICAL INFECTIOUS DISEASES》, vol. 30, 31 May 2000 (2000-05-31), pages 782 * |
孙建军;卢洪洲;: "《艾滋病诊疗指南第三版(2015版)》更新解读", 浙江大学学报(医学版), no. 06, 25 November 2015 (2015-11-25) * |
虞心红;巩玉荣;肖治红;: "抗艾滋病新药硫酸茚地那韦临床研究综述", 天中学刊, no. 02, 15 April 2007 (2007-04-15) * |
陶佩珍: "抗艾滋病病毒药物研究进展", 中国新药杂志, no. 11, 30 November 2002 (2002-11-30) * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Davidson et al. | Drug treatment of tuberculosis—1992 | |
CN107281210B (en) | Application of azithromycin in resisting coronavirus infection | |
US20180153886A1 (en) | Use of trimethazine in preparation of drugs for preventing and treating liver diseases | |
WO2015107482A1 (en) | Pharmaceutical combination for treatment of tuberculosis | |
Petri | Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy | |
CN111265527A (en) | Application of naphthoquine and pharmaceutically acceptable salt thereof in preparation of anti-coronavirus medicines | |
US6362207B1 (en) | Methods of treating viral infections with benzimidazoles | |
Rabinovitch et al. | Acute exfoliative dermatitis and death following penicillin therapy | |
CN117462551A (en) | Application of indinavir and/or derivative thereof in preparation of antituberculosis drugs | |
CN117462552A (en) | Application of itravirin and/or derivatives thereof in preparation of antituberculosis drugs | |
CN109224061B (en) | Application of compound AG120 or pharmaceutically acceptable salt thereof in preparation of drugs for preventing or treating tuberculosis | |
CN112675172B (en) | Application of diketopiperazine compound in preparation of anti-coronavirus drugs | |
Brausch et al. | The treatment of tuberculosis | |
US6479526B1 (en) | Pharmaceutical composition for inhibiting the growth of viruses and cancers | |
CN108440446B (en) | Benzothiazine-4-ketone compound containing oximino fragment and preparation method thereof | |
CN104177373A (en) | Anti-tuberculosis compound IMB-CC223 | |
US5534523A (en) | Anti-aids virus composition | |
US8420660B2 (en) | Antitubercular alkaloid | |
Hinshaw et al. | Present status of chemotherapy in tuberculosis | |
CN109293681B (en) | Antituberculous compound, application thereof in preparation of antituberculous drugs and antituberculous drug composition | |
CN114848634B (en) | Application of SB415286 and Zika virus inhibitor and drug | |
EP0555302A1 (en) | Method of treating demyelinating disease | |
CN116850204A (en) | Application of nano selenium in preparation of medicine for resisting porcine delta coronavirus | |
US20240115521A1 (en) | Compounds for the treatment of mycobacterial diseases | |
Abe et al. | Massive hemoptysis due to mycobacterium fortuitum infection controlled with bronchial artery embolization—a case report |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |